Location History:
- München, DE (2015)
- Munich, DE (2017 - 2023)
Company Filing History:
3 out of 132 
2 out of 1,289 
2 out of 2 
Years Active: 2015-2023
Title: Innovations and Contributions of Inventor Markus Gerhard
Introduction
Markus Gerhard is a prominent inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of T cell receptors and peptides for cancer treatment. With a total of 6 patents, his work has the potential to impact therapeutic strategies for various diseases.
Latest Patents
One of his latest patents focuses on T cell receptors and peptides derived by mutations for the treatment of cancer. This invention relates to a method for providing a neopeptide-specific T cell, wherein the neopeptide-specific T cell forms a complex having a half-life (T½) of at least 50 seconds with a neopeptide-MHC monomer. Additionally, he has developed methods for treating infections, which involve inhibitors of the interaction between HopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family. These innovations also include immunogenic compositions based on HopQ, aimed at preventing or treating diseases associated with this interaction.
Career Highlights
Throughout his career, Markus Gerhard has worked with esteemed institutions such as Technische Universität München and Imevax GmbH. His research and inventions have garnered attention in the scientific community, showcasing his expertise in immunology and biotechnology.
Collaborations
Markus has collaborated with notable colleagues, including Tobias Kruse and Daniel Hornburg. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Markus Gerhard's innovative work in the field of biotechnology, particularly in cancer treatment and infection prevention, highlights his role as a leading inventor. His contributions continue to pave the way for future advancements in medical science.